The most common side effects of GLP-1 medication are gastrointestinal — nausea, diarrhoea, vomiting, and constipation — and for most people they are mild to moderate and concentrated during the period when the dose is increasing. Serious adverse events are rare, but a small number of warnings — relating to the gallbladder, pancreatitis, and thyroid — are worth understanding before starting treatment. This article gives an evidence-based, tiered picture drawn from prescribing information and clinical-trial data.
Dose escalation: the gradual, step-wise increase in medication dose over several weeks or months, used to allow the body to adjust. Side effects are most likely to appear — and most likely to settle — during this phase.
What are the most common side effects?
The most commonly reported side effects with GLP-1 medication are gastrointestinal, and the trial data give specific incidences. With semaglutide 2.4 mg, prescribing information records nausea in 44% of treated adults, diarrhoea in 30%, vomiting in 24%, and constipation in 24%, all compared against lower rates on placebo (Semaglutide 2.4 mg prescribing information). With tirzepatide, a dual GIP/GLP-1 receptor agonist, the figures reported in trials are somewhat lower: nausea up to 29%, diarrhoea up to 23%, constipation up to 17%, and vomiting up to 13% (Tirzepatide prescribing information).
These figures deserve context. They reflect events reported at any point during multi-year trials. In the SURMOUNT-1 trial, the most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation rather than persisting throughout treatment (Jastreboff AM et al., SURMOUNT-1, N Engl J Med 2022). The pattern across both medications is similar: symptoms tend to peak when the dose steps up and ease once the new dose stabilises.
Beyond GI symptoms, other commonly reported events include injection-site reactions, headache, and fatigue — though these occur at lower rates and are generally self-limiting.
How long do side effects last, and can they be reduced?
For most people, gastrointestinal side effects are most prominent during dose escalation and ease once the dose is held steady. This is the clinical rationale for slow, gradual titration schedules — they exist specifically to reduce the severity of these early effects.
Practical steps that can help include eating smaller meals, avoiding high-fat or strongly spiced foods around injection time, staying well hydrated, and injecting at a consistent time each week. None of these substitute for medical guidance, but they are commonly recommended alongside supervised dose management.
When side effects do not settle, or when they are severe enough to affect daily life, GI events are the most common reason people stop treatment. In trials, 4.3% of adults taking semaglutide 2.4 mg discontinued due to gastrointestinal adverse reactions, compared with 0.7% on placebo (Semaglutide 2.4 mg prescribing information — discontinuation). With tirzepatide, discontinuation rates from GI events ranged from 1.9% to 4.3% depending on dose, versus 0.5% on placebo (Tirzepatide prescribing information — discontinuation). These figures represent a minority, but they indicate that side-effect burden should be monitored actively, not managed in isolation.
What is uncommon but worth knowing about?
Gallbladder disease — including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis) — is a recognised, though uncommon, risk with GLP-1 medication. With semaglutide, cholelithiasis occurred in 1.6% of treated adults versus 0.7% on placebo, and the prescribing information lists gallbladder disease as a formal warning (Semaglutide 2.4 mg prescribing information — gallbladder events). With tirzepatide, cholelithiasis was reported in 1.1% and cholecystitis in 0.7% of participants in weight-reduction trials (Tirzepatide prescribing information — gallbladder events).
The likely mechanism relates to reduced gallbladder motility and rapid changes in body composition, both of which can influence bile composition. For most people the absolute risk remains low, but it is higher than in the general population and is listed in prescribing guidance accordingly. Persistent upper-right abdominal pain — particularly after eating — warrants prompt medical review.
What is rare but serious?
Acute pancreatitis — inflammation of the pancreas — has been observed with GLP-1 receptor agonists and is listed as a warning in prescribing information for both semaglutide and tirzepatide (Semaglutide 2.4 mg prescribing information — pancreatitis warning; Tirzepatide prescribing information — pancreatitis warning). This is a warning, not a boxed warning, reflecting a recognised risk that requires clinical awareness rather than automatic contraindication.
The signal is real and should not be dismissed. Acute pancreatitis is, however, a rare event in absolute terms. The prescribing information advises that GLP-1 medication should be discontinued if pancreatitis is confirmed.
Symptoms to be aware of include sudden, severe pain in the upper abdomen that may radiate to the back, often accompanied by nausea and vomiting. This symptom pattern in someone on GLP-1 medication should prompt same-day medical assessment, not a wait-and-see approach.
What about the thyroid cancer warning?
The thyroid C-cell tumour warning attached to both semaglutide and tirzepatide is a boxed warning in the US prescribing information — the most prominent category there. It is worth understanding precisely, neither overstated nor dismissed, and it is worth knowing that the warning is presented differently in different jurisdictions: the European product information carries no boxed-warning equivalent and records the rodent finding in its non-clinical section instead.
The warning is based on rodent studies in which GLP-1 receptor agonists caused dose- and duration-dependent thyroid C-cell tumours in rats and mice (Semaglutide 2.4 mg prescribing information — boxed warning). For tirzepatide, the same finding was observed in rat studies (Tirzepatide prescribing information — boxed warning). The prescribing information for both medications states explicitly that the human relevance of this finding has not been established.
The US prescribing information for both medicines lists a personal or family history of medullary thyroid carcinoma (MTC), or multiple endocrine neoplasia syndrome type 2 (MEN 2), as a contraindication — these being rare but specific conditions in which the thyroid C-cell signal is treated as unacceptable. Singapore's registered product information is structured differently and lists hypersensitivity as its formal contraindication, as the European product information does. Either way, this history is part of a standard pre-treatment medical assessment here, and it is one of the things a doctor asks about before prescribing.
For people without that history, the prescribing information does not indicate a demonstrated elevated risk in humans — but the warning exists because the rodent signal was consistent and the question cannot be fully answered in human populations without long-term follow-up data. A doctor conducting a pre-treatment assessment will weigh this alongside individual history.
When should someone stop and seek medical care?
Mild nausea or loose stools during the first few weeks of a new dose are common and, in isolation, are not an emergency. The following symptoms are different and require prompt medical attention:
- Severe or persistent abdominal pain, particularly upper-right or upper-central, especially after eating
- Pain radiating to the back accompanied by nausea — possible pancreatitis
- Fever with abdominal pain — possible cholecystitis or another acute abdominal event
- Intolerable or prolonged vomiting with inability to keep fluids down
- A neck lump, difficulty swallowing, or hoarseness — worth discussing with a doctor in the context of the thyroid warning
- Any symptom severe enough to affect daily function or that does not improve as the dose stabilises
Self-management is not appropriate for any of the above. GLP-1 medication is a prescription treatment, and side-effect monitoring is part of the clinical supervision that should accompany it. If side effects are poorly tolerated, a treating doctor can adjust the titration schedule, temporarily hold the dose, or consider whether treatment should continue. See also: what happens when you stop GLP-1 medication.
Two of these are about the skin where the needle went rather than about the medicine. Bruises, marks and lumps covers what is ordinary at the injection site and what is not, and your first GLP-1 injection covers what the trials recorded about the injection itself.
Common questions
What are the most common GLP-1 side effects?
The most common side effects are gastrointestinal — nausea, diarrhoea, vomiting, and constipation. With semaglutide 2.4 mg, nausea was reported in 44% of trial participants; with tirzepatide, up to 29% (Semaglutide 2.4 mg prescribing information; Tirzepatide prescribing information). These events are usually mild to moderate and most common during dose escalation.
Does everyone get nausea on GLP-1 medication?
No. Nausea is common but not universal, and it is most likely during the period when the dose is stepping up. In SURMOUNT-1, most gastrointestinal events with tirzepatide were mild to moderate and occurred primarily during dose escalation (Jastreboff AM et al., SURMOUNT-1, N Engl J Med 2022). Once the dose stabilises, symptoms typically ease for most people.
Can GLP-1 medication cause gallstones?
Uncommonly, yes. Cholelithiasis was reported in 1.6% of adults taking semaglutide in trials versus 0.7% on placebo, and in 1.1% of those taking tirzepatide (Semaglutide 2.4 mg prescribing information — gallbladder events; Tirzepatide prescribing information — gallbladder events). Gallbladder disease is listed as a warning in prescribing information for both medications.
Is the thyroid cancer risk real?
The boxed warning is real and should be taken seriously. It is based on rodent studies in which thyroid C-cell tumours were observed — but the prescribing information for both semaglutide and tirzepatide states that human relevance has not been established (Semaglutide 2.4 mg prescribing information — boxed warning; Tirzepatide prescribing information — boxed warning). The hard contraindication is for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.
When should I stop and see a doctor?
Seek medical attention for severe or persistent abdominal pain, symptoms suggesting pancreatitis (upper-abdominal pain radiating to the back, with nausea), intolerable gastrointestinal symptoms that do not improve, or any symptom that concerns you. Dose adjustments and decisions to continue or stop treatment should be made with a doctor, not managed independently.